RCT | Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment.

Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial – The Lancet Oncology

Commentary on Twitter

Updated results from the phase III ICON8 trial in 1,566 pts with newly diagnosed stage IC–IV epithelial ovarian, peritoneal or fallopian tube carcinoma reveal no statistically significant difference in OS with 3-weekly vs weekly carboplatin & paclitaxel: https://t.co/czgH7uGxjt

— NatureRevClinOncol (@NatRevClinOncol) June 15, 2022